Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-006-9001-4
Annals of Surgical Oncology 13:1224-1234 (2006)
© 2006 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, H.-W.
Right arrow Articles by Wu, Y.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.-W.
Right arrow Articles by Wu, Y.-C.

Original Article

Clinical Implications of Microsomal Prostaglandin E Synthase-1 Overexpression in Human Non–Small-Cell Lung Cancer

Hao-Wei Wang, MD1, Chung-Tsen Hsueh, MD, PhD2, Chien-Fu Jeff Lin, MD, PhD3, Teh-Ying Chou, MD, PhD4, Wen-Hu Hsu, MD1, Liang-Shun Wang, MD1 and Yu-Chung Wu, MD1

1 Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, 201, Sec 2, Shih-Pai Road, Taipei 112, Taiwan
2 Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
3 Department of Statistics, National Taipei University, 151 University Road, San Shia, Taipei 237, Taiwan
4 Department of Pathology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, 201, Sec 2, Shih-pai Road, Taipei 112, Taiwan

Correspondence: Address correspondence and reprint requests to: Yu-Chung Wu, MD; E-mail: wuyc{at}vghtpe.gov.tw

Background: Microsomal prostaglandin E synthase-1 (mPGES-1) has recently been found to overexpress in human cancers, including non–small-cell lung cancer (NSCLC). However, the clinical value is largely unknown. The aim of this study was to investigate the associations between mPGES-1 expression in NSCLC and the clinical characteristics and survival outcome.

Methods: Between 2001 and 2003, paired fresh tumorous and nontumorous samples were prospectively procured from patients undergoing surgery for NSCLC. The expression of mPGES-1 was assessed by using Western blot in 93 subjects and reverse transcriptase-polymerase chain reaction in 35. Overexpression of mPGES-1 was defined as a more than 2-fold expression in the tumorous sample compared with the corresponding nontumorous one. Immunohistochemistry was used to confirm its localization to the tumor cells. In a subset of 30 cases, cyclooxygenase-2 (COX-2) was also analyzed to assess its association with mPGES-1.

Results: The protein and messenger RNA of mPGES-1 were both expressed at higher levels in the tumor samples (P < .001 and P = .006, respectively). The expressions of mPGES-1 and COX-2 were unrelated (P = .715). Overexpression of mPGES-1 protein was observed in 61 (65.6%) of 93 patients, but it was not significantly associated with the clinicopathologic characteristics or overall and disease-free survivals. However, mPGES-1 overexpression seemed to be associated with the likelihood of subsequent pulmonary metastases and a lower tendency for developing bony metastases (P = .001 and P = .006, respectively).

Conclusions: Our results demonstrated that mPGES-1 was overexpressed in NSCLC, unassociated with COX-2. Overexpression of mPGES-1 per se was not a prognostic indicator, but it might be implicated in the organ preference of metastasis.

Key Words: Non–small-cell lung cancer • Prostaglandin-endoperoxide synthase • Prostaglandins • Cyclooxygenase inhibitors






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society of Surgical Oncology.